Stock 2197 CLOVER BIOPHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Clover Biopharmaceuticals, Ltd.

Equities

2197

KYG2280A1076

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:06 2024-04-30 am EDT 		5-day change 1st Jan Change
0.345 HKD -.--% Intraday chart for Clover Biopharmaceuticals, Ltd. +4.55% -44.35%
Apr. 12 Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding CI
Apr. 08 Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding
CI
Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial
MT
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
PR
Clover Biopharmaceuticals, Ltd. Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 In Initial Young Adult Cohort
CI
Clover Biopharmaceuticals, Ltd. announced that it expects to receive $0.320713 million in funding
CI
Clover Biopharmaceuticals Trims Losses in 2023
MT
Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sinovac Halts Production of COVID-19 Vaccine as Demand Wanes
MT
Clover Announces Positive Phase ? Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
AQ
Clover Biopharmaceuticals Publishes Positive Results from SCB-219M Clinical Trial
MT
Clover Biopharmaceuticals, Ltd. Announces Positive Phase I Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia
CI
Clover Biopharmaceuticals Completes Patient Enrollment for Australia Phase 1 Trial; Shares Fall 5%
MT
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
PR
Clover Biopharmaceuticals, Ltd. Initiates Phase Clinical Trial for RSV Vaccine Candidate
CI
Clover Biopharmaceuticals Completes Submission of Application for Seasonal Flu Vaccine in Brazil
MT
Clover Biopharmaceuticals, Ltd. Completes Biologic License Application for Its Seasonal Influenza Vaccine in Brazil
CI
Clover Biopharmaceuticals Rolls Out Quadrivalent Seasonal Influenza Vaccine in Mainland China
MT
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
GL
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
AQ
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland China
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2197 Stock
  4. News Clover Biopharmaceuticals, Ltd.